AYTU

Dopo l'orario di chiusura: 1.60

Aytu Biopharma Inc (AYTU)

Panoramica Notizia Cronologia dei prezzi Financials Perché AYTU Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Aytu Biopharma Inc Stock (AYTU) Company Profile

Aytu Biopharma Inc

Healthcare (1196)

(720) 437-6580

7900 E. UNION AVENUE, DENVER

@aytubioscience

Prossima data di guadagno

Ultimi documenti SEC

AYTU's Discussions on Twitter

Confronta AYTU con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AYTU	1.60	9.78M	93.76M	-13.68M	8.77M	-10.27
ZTS	176.42	79.51B	9.15B	2.43B	2.31B	4.92
TAK	13.53	42.89B	30.27B	1.93B	3.45B	0.444
HLN	9.43	42.57B	14.26B	1.55B	0	0.3327
TEVA	16.49	18.51B	16.77B	-959.00M	1.37B	-2.00
VTRS	13.00	15.37B	15.24B	-646.50M	1.88B	1.53

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-03-30	Iniziato	Cantor Fitzgerald	Overweight
2020-05-29	Iniziato	H.C. Wainwright	Buy

Aytu Biopharma Inc Borsa (AYTU) Ultime notizie

Aytu Biopharma Inc Azioni (AYTU) Dati Finanziari

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc Stock (AYTU) Company Profile

Confronta AYTU con altri titoli

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Aytu Biopharma Inc Borsa (AYTU) Ultime notizie

Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Aytu BioPharma Announces Fiscal 2025 First Quarter Results and CFO Transition - Defense World

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript - Insider Monkey

Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32% - Simply Wall St

Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com

Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Hi - GuruFocus.com

Aytu BioPharma Reports Q1 Fiscal 2025 Earnings - TipRanks

Stonepine Capital Management's Strategic Acquisition in Aytu Bio - GuruFocus.com

Aytu BioPharma Names Ryan Selhorn as CFO - MarketWatch

Aytu Biopharma, Inc. Announces Chief Financial Officer Changes - Marketscreener.com

Differentiated Rx brands focused on ADHD and Pediatrics – Aytu BioPharma (NASDAQ: AYTU) | GCFF - NAI 500

Aytu BioScience stock hits 52-week low at $1.8 amid market challenges - Investing.com Australia

Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics - The Globe and Mail

Vascular Ehlers-Danlos Syndrome Market on Track for Major - openPR

Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly? - Simply Wall St

AYTU stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail

AYTU stock touches 52-week low at $2.07 amid market challenges - Investing.com

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit - AccessWire

Aytu BioScience stock hits 52-week low at $2.2 amid market challenges - Investing.com Australia

Aytu BioScience stock hits 52-week low at $2.2 amid market challenges By Investing.com - Investing.com South Africa

Aytu BioPharma’s Exclusive Agreement with Lupin Pharma Canada Ltd - Global Legal Chronicle

Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini

Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada - Investing.com Canada

Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada By Investing.com - Investing.com South Africa

AYTUAYTU BioPharma, Inc. Latest Stock News & Market Updates - StockTitan

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - StockTitan

Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Earnings call: Aytu BioPharma reports turnaround with focus on ADHD By Investing.com - Investing.com South Africa

Earnings call: Aytu BioPharma reports turnaround with focus on ADHD - Investing.com

When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - Simply Wall St

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results - AccessWire

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 - AccessWire

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha

Balance Sheet Insights: Atyr Pharma Inc (ATYR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Anterix (NASDAQ:ATEX) Sees Unusually-High Trading Volume - Defense World

Atlantica Sustainable Infrastructure (NASDAQ:AY) Now Covered by StockNews.com - Defense World

Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug - Benzinga

Altamira Therapeutics announces pricing of $12M offering - TipRanks

Jupiter Asset Management Ltd. Makes New Investment in Anterix Inc. (NASDAQ:ATEX) - Defense World

Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - Yahoo Finance

Comparing Sanofi (NASDAQ:SNY) & Aytu BioPharma (NASDAQ:AYTU) - Defense World

Alaska Air clears hurdle in proposed merger with Hawaiian Airlines - Head Topics

Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Update - Defense World

Aytu BioPharma (NASDAQ:AYTU) Share Price Crosses Below 50 Day Moving Average of $2.77 - Defense World

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 - AccessWire

Aytu Biopharma Inc Azioni (AYTU) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a AYTU